Factors that influence the appearance of central nervous system leukemia.
D002493:Central Nervous System Diseases / Q000473:pathology* / Q000532:radiotherapy; D002555:Cerebrospinal Fluid / Q000166:cytology; D003037:Cobalt Radioisotopes; D003630:Daunorubicin / Q000627:therapeutic use; D006801:Humans; D007278:Injections, Spinal; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000473:pathology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000473:pathology; D007958:Leukocyte Count; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011867:Radioisotope Teletherapy; D012008:Recurrence; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use
D003037:Cobalt Radioisotopes; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin